JP2012510477A - 放射性医用薬剤としての窒素含有大環状結合体 - Google Patents

放射性医用薬剤としての窒素含有大環状結合体 Download PDF

Info

Publication number
JP2012510477A
JP2012510477A JP2011538797A JP2011538797A JP2012510477A JP 2012510477 A JP2012510477 A JP 2012510477A JP 2011538797 A JP2011538797 A JP 2011538797A JP 2011538797 A JP2011538797 A JP 2011538797A JP 2012510477 A JP2012510477 A JP 2012510477A
Authority
JP
Japan
Prior art keywords
group
optionally substituted
formula
compound
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011538797A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012510477A5 (enExample
Inventor
ポール ステファン ドネリー
ミシェル テレス マ
デニス バーナード スキャンロン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Melbourne
Original Assignee
University of Melbourne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2008906239A external-priority patent/AU2008906239A0/en
Application filed by University of Melbourne filed Critical University of Melbourne
Publication of JP2012510477A publication Critical patent/JP2012510477A/ja
Publication of JP2012510477A5 publication Critical patent/JP2012510477A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D521/00—Heterocyclic compounds containing unspecified hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/106—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from kidney or bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2011538797A 2008-12-02 2009-12-02 放射性医用薬剤としての窒素含有大環状結合体 Pending JP2012510477A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2008906239A AU2008906239A0 (en) 2008-12-02 Radiopharmaceuticals
AU2008906239 2008-12-02
PCT/AU2009/001572 WO2010063069A1 (en) 2008-12-02 2009-12-02 Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015022109A Division JP5981580B2 (ja) 2008-12-02 2015-02-06 放射性医用薬剤としての窒素含有大環状結合体

Publications (2)

Publication Number Publication Date
JP2012510477A true JP2012510477A (ja) 2012-05-10
JP2012510477A5 JP2012510477A5 (enExample) 2013-01-24

Family

ID=42232814

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011538797A Pending JP2012510477A (ja) 2008-12-02 2009-12-02 放射性医用薬剤としての窒素含有大環状結合体
JP2015022109A Active JP5981580B2 (ja) 2008-12-02 2015-02-06 放射性医用薬剤としての窒素含有大環状結合体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015022109A Active JP5981580B2 (ja) 2008-12-02 2015-02-06 放射性医用薬剤としての窒素含有大環状結合体

Country Status (9)

Country Link
US (8) US9701694B2 (enExample)
EP (2) EP2370447B1 (enExample)
JP (2) JP2012510477A (enExample)
CN (1) CN102300866B (enExample)
AU (1) AU2009322081C1 (enExample)
CA (1) CA2745495C (enExample)
DK (1) DK3098225T3 (enExample)
ES (1) ES2712881T3 (enExample)
WO (1) WO2010063069A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019533728A (ja) * 2016-11-04 2019-11-21 クラリティー・ファーマシューティカルズ・プロプライエタリー・リミテッド 放射線治療及び画像診断のための製剤
KR20200011950A (ko) * 2017-06-06 2020-02-04 더 유니버시티 오브 멜버른 방사성 의약품, 방사성 영상화제 및 이의 용도
JP2023516878A (ja) * 2020-01-26 2023-04-21 メインライン バイオサイエンシーズ（シャンハイ）シーオー．，エルティーディ． 同位体標識された選択的ｃｘｃｒ４結合性ペプチドコンジュゲート並びにその作製方法及び使用方法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6207504B2 (ja) 2011-07-07 2017-10-04 オーストラリアン ニュークリア サイエンス アンド テクノロジー オーガニゼーション クリプテート化合物
WO2013082655A1 (en) * 2011-12-06 2013-06-13 The University Of Melbourne Functionalisation of cage amine ligands for metallo-radiopharmaceuticals
DK2788353T3 (da) * 2011-12-06 2022-08-15 Clarity Pharmaceuticals Ltd Bur-aminligander til metallo-radiofarmaceutika
US9422286B2 (en) 2014-01-27 2016-08-23 Washington University Metal-binding bifunctional compounds as diagnostic agents for Alzheimer's disease
GB201417067D0 (en) 2014-09-26 2014-11-12 South African Nuclear Energy Radiopharmaceutical conjugate
AU2019251769A1 (en) * 2018-04-11 2020-10-15 Clarity Pharmaceuticals Limited Formulations and kits for radiotherapy and diagnostic imaging
CN111989324A (zh) * 2018-04-11 2020-11-24 墨尔本大学 靶向化合物及其生产方法
EP3976025A4 (en) * 2019-05-24 2023-05-17 Clarity Pharmaceuticals Limited PSMA IMAGING AGENT FORMULATIONS
WO2021087568A1 (en) * 2019-11-08 2021-05-14 The University Of Queensland Radiolabelled targeting ligands
JP7894086B2 (ja) * 2020-05-06 2026-07-23 コーネル ユニヴァーシティー 銅含有セラグノスティック化合物及びその使用の方法
EP4196175A4 (en) * 2020-08-14 2025-07-30 Clarity Pharmaceuticals Ltd RADIOPHARMACEUTICAL COMPOUNDS, THEIR USES AND PROCESSES FOR THEIR PRODUCTION
AU2023322240A1 (en) * 2022-08-11 2025-02-20 Clarity Pharmaceuticals Limited Dimeric radiopharmaceuticals, compositions thereof and uses thereof
CN116589508A (zh) * 2023-05-16 2023-08-15 洛阳师范学院 一种基于半夹心铑构筑单元的矩形分子大环化合物及其制备方法和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04244085A (ja) * 1990-12-21 1992-09-01 Doujin Kagaku Kenkyusho:Kk 蛍光性化合物、錯体、試薬および該試薬を用いる特異的結合アッセイ
WO1995031202A1 (en) * 1994-05-17 1995-11-23 Commonwealth Scientific And Industrial Research Organisation Cage compounds, processes for their preparation and their use as antiviral agents
US6107326A (en) * 1999-04-12 2000-08-22 Cytopharm, Inc. Porphycenes for treatment of microbial populations
JP2005500325A (ja) * 2001-07-10 2005-01-06 アメルシャム・パブリック・リミテッド・カンパニー 改良キレート剤結合体
JP2005515842A (ja) * 2002-01-29 2005-06-02 ブラッコ　イメージング　エッセ　ピ　ア 応答性常磁性ｍｒｉ造影剤
JP2008505049A (ja) * 2003-10-17 2008-02-21 シーティーティー キャンサー ターゲッティング テクノロジーズ オイ ターゲティング組成物及びその製造方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0001719A1 (en) 1977-10-26 1979-05-02 The Australian National University Metal complexes, their preparation and production of hydrogen peroxide therewith
CN1033030C (zh) * 1988-06-24 1996-10-16 唐化学原料公司 大环双官能螯合剂及其配合物和抗体共轭物的制备方法
US5245055A (en) * 1990-12-18 1993-09-14 E. R. Squibb & Sons, Inc. Process for preparing a cis oxabicyclo olefinic acid and ester from an oxabicyclo pyranol
CZ307096A3 (en) * 1994-04-22 1997-09-17 Monsanto Co Methods of video analysis by making use of metal complexes of nitrogen-containing macrocyclic ligands
AUPP803899A0 (en) * 1999-01-05 1999-01-28 Australian National University, The Cryptate compounds and methods for diagnosis and therapy.
WO2008147481A1 (en) * 2007-02-09 2008-12-04 Northeastern University Precision-guided nanoparticle systems for drug delivery

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04244085A (ja) * 1990-12-21 1992-09-01 Doujin Kagaku Kenkyusho:Kk 蛍光性化合物、錯体、試薬および該試薬を用いる特異的結合アッセイ
WO1995031202A1 (en) * 1994-05-17 1995-11-23 Commonwealth Scientific And Industrial Research Organisation Cage compounds, processes for their preparation and their use as antiviral agents
US6107326A (en) * 1999-04-12 2000-08-22 Cytopharm, Inc. Porphycenes for treatment of microbial populations
JP2005500325A (ja) * 2001-07-10 2005-01-06 アメルシャム・パブリック・リミテッド・カンパニー 改良キレート剤結合体
JP2005515842A (ja) * 2002-01-29 2005-06-02 ブラッコ　イメージング　エッセ　ピ　ア 応答性常磁性ｍｒｉ造影剤
JP2008505049A (ja) * 2003-10-17 2008-02-21 シーティーティー キャンサー ターゲッティング テクノロジーズ オイ ターゲティング組成物及びその製造方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6014010417; Ｌｅｎｇｋｅｅｋ，　Ｎ．Ａ．: 'Ｆｕｎｃｔｉｏｎａｌ　Ｃａｇｅ-Ａｍｉｎｅ　Ｃｏｍｐｌｅｘｅｓ：　Ｐｏｌｙｍｅｒｉｓａｂｌｅ　Ｍｅｔａｌｌｏｍｏｎｏｍｅｒｓ　ａｎｄ　Ｍｕｌｔｉ-Ｃａｇｅ　Ｃｏｍｐｌｅｘｅｓ．' ＰｈＤ　Ｔｈｅｓｉｓ，　Ｕｎｉｖｅｒｓｉｔｙ　ｏｆ　Ｗｅｓｔｅｒｎ　Ａｕｓｔｒａｌｉａ , 2007, ｐｐ．８，　９，　２０２-２０４，　２１１-２１２，　２１４-２１８ *
JPN7014000806; ＢＡＬＥＳ，Ｂ．Ｃ．　ｅｔ　ａｌ: 'Ｍｅｃｈａｎｉｓｔｉｃ　ｓｔｕｄｉｅｓ　ｏｎ　ＤＮＡ　ｄａｍａｇｅ　ｂｙ　ｍｉｎｏｒ　ｇｒｏｏｖｅ　ｂｉｎｄｉｎｇ　ｃｏｐｐｅｒ-ｐｈｅｎａｎｔｈｒｏｌｉｎｅ　ｃｏｎｊｕｇａｔｅｓ' Ｎｕｃｌｅｉｃ　Ａｃｉｄｓ　Ｒｅｓｅａｒｃｈ Ｖｏｌ．３３，　Ｎｏ．１６, 2005, ｐｐ．５３７１-５３７９ *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019533728A (ja) * 2016-11-04 2019-11-21 クラリティー・ファーマシューティカルズ・プロプライエタリー・リミテッド 放射線治療及び画像診断のための製剤
JP7242538B2 (ja) 2016-11-04 2023-03-20 クラリティー・ファーマシューティカルズ・リミテッド 放射線治療及び画像診断のための製剤
KR20200011950A (ko) * 2017-06-06 2020-02-04 더 유니버시티 오브 멜버른 방사성 의약품, 방사성 영상화제 및 이의 용도
JP2020522478A (ja) * 2017-06-06 2020-07-30 ザ ユニヴァーシティー オブ メルボルン 放射性医薬品、放射線造影剤及びそれらの使用
JP7144451B2 (ja) 2017-06-06 2022-09-29 クラリティー・ファーマシューティカルズ・リミテッド 放射性医薬品、放射線造影剤及びそれらの使用
JP2022184952A (ja) * 2017-06-06 2022-12-13 クラリティー・ファーマシューティカルズ・リミテッド 放射性医薬品、放射線造影剤及びそれらの使用
KR102644075B1 (ko) 2017-06-06 2024-03-07 클라리티 파마슈티컬스 리미티드 방사성 의약품, 방사성 영상화제 및 이의 용도
JP7506121B2 (ja) 2017-06-06 2024-06-25 クラリティー・ファーマシューティカルズ・リミテッド 放射性医薬品、放射線造影剤及びそれらの使用
JP2023516878A (ja) * 2020-01-26 2023-04-21 メインライン バイオサイエンシーズ（シャンハイ）シーオー．，エルティーディ． 同位体標識された選択的ｃｘｃｒ４結合性ペプチドコンジュゲート並びにその作製方法及び使用方法

Also Published As

Publication number Publication date
US20170267699A1 (en) 2017-09-21
EP3098225A1 (en) 2016-11-30
US20240190897A1 (en) 2024-06-13
CN102300866B (zh) 2015-08-26
US20200115391A1 (en) 2020-04-16
US20210363161A1 (en) 2021-11-25
AU2009322081B2 (en) 2016-05-26
ES2712881T3 (es) 2019-05-16
US20110293517A1 (en) 2011-12-01
EP2370447B1 (en) 2016-07-27
CA2745495A1 (en) 2010-06-10
AU2009322081C1 (en) 2016-09-01
US12565506B2 (en) 2026-03-03
EP3098225B1 (en) 2018-11-28
JP5981580B2 (ja) 2016-08-31
US9701694B2 (en) 2017-07-11
CN102300866A (zh) 2011-12-28
US20170267698A1 (en) 2017-09-21
EP2370447A4 (en) 2013-08-14
JP2015145367A (ja) 2015-08-13
AU2009322081A1 (en) 2011-07-21
US20260226078A1 (en) 2026-08-06
US11905301B2 (en) 2024-02-20
US20190225625A1 (en) 2019-07-25
CA2745495C (en) 2017-07-18
US10870664B2 (en) 2020-12-22
WO2010063069A1 (en) 2010-06-10
US10544164B2 (en) 2020-01-28
US11111254B2 (en) 2021-09-07
US10301326B2 (en) 2019-05-28
DK3098225T3 (en) 2019-03-25
EP2370447A1 (en) 2011-10-05

Similar Documents

Publication Publication Date Title
JP5981580B2 (ja) 放射性医用薬剤としての窒素含有大環状結合体
JP6047581B2 (ja) 金属放射性医薬品のためのケージアミン配位子
US9364570B2 (en) Functionalisation of cage amine ligands for metallo-radiopharmaceuticals
HK40080888A (en) Cage amine ligands for metallo-radiopharmaceuticals
CN120344273A (zh) 二聚体放射性药物、其组合物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140310

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140605

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140910

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141008